Generic Name and Formulations:
Crofelemer 125mg; delayed-release tablets; enteric-coated.
Napo Pharmaceuticals, Inc.
Indications for MYTESI:
Symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.
Swallow whole. One tab twice daily.
<18yrs: not established.
Rule out infectious etiologies of diarrhea before starting. Pregnancy (Cat. C). Nursing mothers: not recommended.
Upper respiratory tract infection, bronchitis, cough, flatulence, increased bilirubin.
Formerly known under the brand name Fulyzaq.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Improving Performance of Everyday Activities Is Critical in Schizophrenia
- Analysis Finds Lithium Maintenance Most Effective as Monotherapy in Bipolar Disorder
- Web-Based Intervention Targets Parental Behaviors That May Affect Adolescent Anxiety, Depression
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders
- Mortality Rates for Substance Use Disorders, Intentional Injuries Vary Widely By Country
- Facial Emotion Recognition Differentiates Behavioral Variant Frontotemporal Dementia From MDD
- The Challenge of Helping Uninsured Patients While Protecting Practice Finances
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed